Arrowhead Pharmaceuticals Completes Patient Enrollment In Its Global Phase 3 YOSEMITE Clinical Study Of Zodasiran To Treat Homozygous Familial Hypercholesterolemia
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed enrollment in the global Phase 3 YOSEMITE clinical trial of zodasiran, the company’s investigational RNA interference (RNAi)
Arrowhead finished enrolling all the patients it needed for a big test of a new medicine called zodasiran that could help people with very high cholesterol. This is an important checkpoint—now the company will watch to see if the medicine actually works before asking for permission to sell it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.